Serum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin

Br J Cancer. 1986 Jul;54(1):67-73. doi: 10.1038/bjc.1986.153.

Abstract

Sera from 31 HBsAg-positive Chinese patients with inoperable hepatocellular carcinoma (HCC) were tested for hepatitis B virus DNA (HBV DNA) by means of dot hybridisation and Southern blot technique. HBV DNA probes were prepared from human plasma. Eighteen of the patients were HBeAb-positive, 12 were HBeAg-positive and one case had neither marker. Serial specimens were obtained from 16 cases over 5-42 weeks, while the patients were treated with recombinant leukocyte A interferon (rIFN-A) or adriamycin. Seven patients (2 HBeAg-positive, 5 HBeAb-positive) were positive for HBV DNA. In two patients HBV DNA and HBV DNA polymerase (DNAp) appeared in serum weeks after rIFN-A or adriamycin treatment was started. In two other cases, HBV DNA that was initially present disappeared during rIFN-A treatment. In a fifth patient HBV DNA persisting after adriamycin treatment diminished after change of treatment to rIFN-A. With one possible exception the HBV DNA detectable by Southern blot technique was composed chiefly of sequences 2.2-3.2 kb size indicating the presence of unintegrated DNA forms. DNAp activities were raised in the presence of HBV DNA in 4 patients. These findings show that HBV replication can be activated or suppressed in advanced HCC. Treatment with rIFN-A may have been effective in suppressing HBV DNA synthesis, but the number of cases studied was too small to arrive at a definite conclusion on this point.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Base Sequence
  • Carcinoma, Hepatocellular / blood*
  • Carcinoma, Hepatocellular / drug therapy
  • DNA, Viral / metabolism*
  • Doxorubicin / therapeutic use*
  • Electrophoresis, Agar Gel
  • Hepatitis B Surface Antigens / analysis
  • Hepatitis B virus / metabolism*
  • Humans
  • Interferon Type I / therapeutic use*
  • Liver Neoplasms / blood*
  • Liver Neoplasms / drug therapy
  • Nucleic Acid Hybridization

Substances

  • DNA, Viral
  • Hepatitis B Surface Antigens
  • Interferon Type I
  • Doxorubicin